Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597

Abstract

A B S T R A C T PurposeSelenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation. Patients and MethodsPatients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200 g versus placebo daily for 48 months. Participation was 6 to 36 months postoperatively and required a negative mediastinal node biopsy, no excessive vitamin intake, normal liver function, negative chest x-ray, and no other evidence of recurrence. ResultsThe first interim analysis in October 2009, with 46% of the projected end points accumulated, showed a trend in favor of the placebo group with a low likelihood that the trial would become positive; thus, the study was stopped. One thousand seven hundred seventy-two participants were enrolled, with 1,561 patients randomly assigned. Analysis was updated in June 2011 with the maturation of 54% of the planned end points. Two hundred fifty-two SPTs (from 224 patients) developed, of which 98 (from 97 patients) were lung cancer (38.9%). Lung and overall SPT incidence were 1.62 and 3.54 per 100 person-years, respectively, for selenium versus 1.30 and 3.39 per 100 person-years, respectively, for placebo (P ϭ .294). Five-year disease-free survival was 74.4% for selenium recipients versus 79.6% for placebo recipients. Grade 1 to 2 toxicity occurred in 31% of selenium recipients and 26% of placebo recipients, and grade Ն 3 toxicity occurred in less than 2% of selenium recipients versus 3% of placebo recipients. Compliance was excellent. No increase in diabetes mellitus or skin cancer was detected. ConclusionSelenium was safe but conferred no benefit over placebo in the prevention of SPT in patients with resected NSCLC.

Inhibition of Nox4‐dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal‐mediated protumorigenic interactions

“…Several prominent clinical trials however employing dietary antioxidants yielded disappointing anticancer results 42, 43, 44. Thus, current consensus is that rather than attempting to neutralize ROS, treatment strategies aimed at reducing ROS production might represent an effective alternative approach 45.…”

Reactive oxygen species in redox cancer therapy

“…Indeed, the statistical results showed that high-dosage Vitamin E supplement (> or =400 IU/d) increased mortality and should be avoided [65]. On the other hand, Se is believed to be safe to use but showed no benefit to non-smallcell lung cancer [51]. Other clinical trials also indicated that Vitamin E intake increased the risk of prostate cancer, and Se supplementation intake could increase the prostate cancer risk in men with preexisting high levels of Se [50].…”

AJRCCM: 100-Year Anniversary.The Shifting Landscape for Lung Cancer: Past, Present, and Future

“…Early chemoprevention trials focused on vitamin A and beta carotene failed to show a protective effect, and some trials suggested a potential increase in lung cancer risk (11)(12)(13). Furthermore, a recent phase III trial failed to demonstrate efficacy for selenium supplementation (14). There are, however, a number of agents, including iloprost (15), myoinositol (16), and cyclooxygenase-2 inhibitors, that are currently being explored in early-phase trials.…”